BC
AERI

Broadfin Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Broadfin Capital’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-64,800
Closed -$3.15M – 53
2017
Q3 		$3.15M Sell
64,800
-245,200
-79% -$13.4M 0.47% 39
2017
Q2 		$16.3M Buy
+310,000
New +$14.4M 1.98% 17
2014
Q1 		– Sell
-391,232
Closed -$7.03M – 90
2013
Q4 		$7.03M Buy
+391,232
New +$5.1M 0.93% 36

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Broadfin Capital's AERI Position: Q4 2017 in Review

Broadfin Capital sold out of Aerie Pharmaceuticals (AERI) in Q4 2017, closing a stake of 64,800 shares — an estimated $3.15M sold.

Broadfin Capital first reported a position in AERI in Q4 2013 and held it in 3 quarters. The position peaked at $16.3M in Q2 2017. 179 funds tracked by Wall St. Rank hold AERI as of Q4 2017.

  • Broadfin Capital reported no remaining Aerie Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Broadfin Capital sold 64,800 Aerie Pharmaceuticals shares in Q4 2017, an estimated $3.15M.
  • Broadfin Capital first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • Broadfin Capital's Aerie Pharmaceuticals position peaked at $16.3M in Q2 2017.
  • 179 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2017.

Based on Broadfin Capital's 13F filing for Q4 2017, filed 13 Feb 2018.